Assessment of renal function during high-dose cis-platinum therapy in patients with ovarian carcinoma.
Five courses of cis-dichlorodiammine platinum (II) (100 mg/m2) were given to 22 patients with advanced stage III and IV ovarian cancer. Renal function was assessed by measurement of creatinine clearance, urinary osmolality and urinary B2-microglobulin (B2MG) in all patients, and by urinary alanine aminopeptidase (AAP) and N-acetyl-B-glucosaminidase (NAG) excretion in seven patients. Serum creatinine, creatinine clearance, urinary osmolality, and urinary B2-microglobulin were within the reference ranges and did not change significantly after five courses of cis-platinum in any patient. There was a significant increase in the urinary excretion of both enzymes (AAP and NAG) within 2 days of cis-platinum administration (NAG P less than 0.05 and AAP P less than 0.07). There was evidence of a cumulative effect during treatment for AAP (P less than 0.025).
D000118:Acetylglucosaminidase / Q000652:urine; D000328:Adult; D000626:Aminopeptidases / Q000652:urine; D018826:CD13 Antigens; D002945:Cisplatin / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007668:Kidney / Q000187:drug effects* / Q000378:metabolism; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D001613:beta 2-Microglobulin / Q000652:urine
D001613:beta 2-Microglobulin; D000118:Acetylglucosaminidase; D000626:Aminopeptidases; D018826:CD13 Antigens; D002945:Cisplatin